Skip to main content
. 2015 Jun 4;2015:719316. doi: 10.1155/2015/719316

Figure 3.

Figure 3

(a) CTA 157-2 specifically activates 20S proteasome and (b) control IgM antibody is without effect. (c) Proteasome inhibitor lactacystin reduces proteasome activity as expected. (d) Activation of the proteasome is purified membrane preparations with CTA 157-2 treatment.